Lung Cancer Clinical Trial
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
Summary
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
Eligibility Criteria
Inclusion Criteria:
Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.
Have received no prior chemotherapy for your disease.
Have at least one measurable lesion.
have an adequate performance status.
Sign an informed consent form.
Exclusion Criteria:
Have previously received chemotherapy for your lung cancer.
Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.
Have received radiation therapy within the last 1-2 weeks.
Have brain metastasis that is uncontrolled.
Have active infection or other serious condition.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Springdale Arkansas, , United States
Los Angeles California, , United States
Fort Myers Florida, , United States
Miami Florida, , United States
Latham New York, , United States
Burlington North Carolina, , United States
Chapel Hill North Carolina, , United States
Charleston South Carolina, , United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.